Enzychem Lifesciences Applies for US 'COVID-19 Treatment Development Project'

[Asia Economy Reporter Koh Hyung-kwang] Engchem Life Sciences announced on the 24th that it has submitted a research proposal for 'EC-18 to prevent the progression of COVID-19 infection to severe pneumonia or acute respiratory distress syndrome (ARDS)' to the U.S. Department of Health's COVID-19 treatment development funding project (BARDA BAA) and applied for emergency funding. The budget support amount requested by Engchem Life Sciences is $35 million (approximately 40 billion KRW).

The BARDA BAA project, promoted by the U.S. Department of Health and Human Services (HHS) and the Biomedical Advanced Research and Development Authority (BARDA), is an emergency medical countermeasure (MCM) system for urgent drug development in response to emergencies such as COVID-19. If selected for the program, the company receives full financial support from BARDA for costs related to clinical trials and development, allowing it to focus on treatment development.

Engchem Life Sciences explained, "The new drug substance EC-18 is a groundbreaking platform technology that enables immune cells to rapidly engulf and eliminate viruses and bacteria, and suppress the cytokine storm, which is a major cause of death in COVID-19," adding, "We applied for the BARDA BAA project based on numerous international academic papers and clinical trials."

This content was produced with the assistance of AI translation services.